# Iván Márquez‐Rodas

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ivan-marquez-rodas/

## Facts

| Field | Value |
| --- | --- |
| Citations | 29,739 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 41 |
| i10-index | 97 |
| Last Known Institution | Hospital General Universitario Gregorio Marañón |
| OpenAlex ID | https://openalex.org/A5068684456 |
| ORCID iD | https://orcid.org/0000-0002-2476-668X |
| Works | 310 |

## Researcher papers

- [Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-nivolumab-versus-ipilimumab-in-resected-stage-iiib-c-and-stage-iv/)
- [ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee](https://scholariq.org/papers/esmo-consensus-conference-recommendations-on-the-management-of-metastatic/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

## Researcher university

- [Hospital General Universitario Gregorio Marañón](https://scholariq.org/institutions/hospital-general-universitario-gregorio-maranon/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.